Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Superficial thrombophlebitis

Cardiology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Escalate

New whole-limb swelling, chest pain, breathlessness, haemoptysis or syncope requires urgent DVT/PE assessment. Rapid extension to the groin/popliteal fossa or SVT within 3 cm of a deep-vein junction needs same-day thrombosis review.

Synopsis

Distinguish low-risk superficial vein thrombosis from disease near the deep system, exclude concomitant DVT and use evidence-based anticoagulation when extension risk is material.

  • Superficial vein thrombosis (SVT) produces a tender, erythematous, palpable cord along a superficial vein; it is not always benign.
  • Duplex ultrasound should define thrombus length, distance from the saphenofemoral/saphenopopliteal junction and any concomitant DVT when disease is extensive, proximal or clinically uncertain.
  • SVT at least 5 cm long and at least 3 cm from a deep-vein junction is treated with fondaparinux 2.5 mg subcutaneously once daily for 45 days when suitable.
  • SVT within 3 cm of a deep-vein junction is managed as high-risk extension with therapeutic anticoagulation, usually for 3 months after specialist assessment.
  • A short SVT below 5 cm and more than 3 cm from the deep system, without high-risk features, can usually receive mobilisation, local measures and analgesia/NSAID rather than anticoagulation.
  • Cancer, previous VTE, thrombophilia, pregnancy, recent surgery, non-varicose-vein SVT and rapid progression lower the threshold for imaging and specialist treatment.
  • Do not prescribe antibiotics unless there is separate cellulitis, suppuration or another bacterial infection; erythema over thrombus is inflammatory.
  • After the acute episode, assess symptomatic varicose veins/venous reflux because definitive venous treatment may reduce recurrence.

Key red flags

Proximal extension

Cord or inflammation approaching the groin or popliteal fossa, rapid proximal spread or extensive length raises deep-system extension risk.

Concomitant DVT

Whole-leg swelling, deep calf tenderness, pitting oedema or risk factors out of proportion to the superficial segment require the NICE DVT pathway.

Pulmonary embolism

New dyspnoea, pleuritic pain, haemoptysis, tachycardia, syncope or hypoxia requires emergency PE assessment.

Investigation priorities

01
Whole-leg duplex ultrasoundFirst step

Confirm SVT length and location, measure distance to deep junctions and exclude DVT.

Management branches

low riskShort distal SVT

SVT <5 cm long, >3 cm from a deep junction, no DVT and no major extension-risk feature.

  1. First: encourage mobilisation as tolerated, limb elevation when resting and warm/cool compresses according to comfort.
  2. Next: offer topical/oral NSAID or paracetamol if safe; avoid antibiotics without infection.
  3. Next: give explicit return advice for proximal spread, whole-leg swelling or PE symptoms.
  4. Escalation: arrange duplex/reassessment if symptoms extend or fail to improve over about a week.

Key medicines

Fondaparinux2.5 mg subcutaneously once daily for 45 days (licensed course is a minimum of 30 and maximum of 45 days in the eligible high-risk population).Do not use this low-dose regimen for SVT within 3 cm of the junction. Contraindicated if CrCl <20 mL/min; reduce to 1.5 mg daily at CrCl 20–50 mL/min, noting that this reduced dose has not been studied for efficacy/safety. For the SVT indication the SmPC does not recommend fondaparinux below 50 kg, and active cancer/recent VTE were not studied.
Ibuprofen400 mg orally three times daily with/after food for up to 5–7 days when needed.Avoid or minimise with anticoagulation, peptic ulcer, CKD, heart failure, uncontrolled hypertension or pregnancy; topical NSAID may have less systemic exposure.
Open full textbook →Answer 2 questionsCardiology check
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • ESVS 2021 Clinical Practice Guidelines on Venous ThrombosisSVT anatomical risk bands and anticoagulation duration.
  • eMC: Arixtra 2.5 mg SmPCLicensed SVT population, 2.5 mg dose, duration and renal modifiers.
  • NHS: PhlebitisRecognition and urgent symptom advice.
  • NICE NG158: Venous thromboembolic diseasesDVT/PE pathway when deep extension is suspected or confirmed.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom